Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic

Executive Summary

Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.

You may also be interested in...



Cipla-SIGA Antibacterial Alliance To Tackle Resistance, Biothreats

Cipla, which has long-standing experience in antibiotic development in India, strikes alliance with US firm SIGA Technologies. The partners are targeting novel antibacterials, especially against biothreats, and expect to cater to US agency BARDA, among others.

One More On QIDP List – Does It Help Wockhardt?

Wockhardt has received QIDP designation in the US for its once-daily zidebactam-based combination antibiotic WCK 6777, taking to six its portfolio products with the status. But unless the FDA gives a clean sheet to the company’s major manufacturing units, this won't help US revenues 

Wockhardt Will Raise Funds With Restructuring

India’s Wockhardt has announced its first profit in three years and says a restructuring plan will be carried out soon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel